Abstract
Lung cancer is the most commonly diagnosed malignancy and the leading cause of cancer mortality worldwide. Radiation therapy (RT) plays an important role in the management of both small cell (SCLC) and non-small cell lung cancer (NSCLC), as 50 to 60% of patients diagnosed with lung cancer will require RT during the course of their disease. In NSCLC, in addition to the use of RT in advanced stage disease, inoperable patients with early-stage disease are now being treated with highly conformal hypofractionated RT as well as radiosurgery. In SCLC, the use of thoracic chemo-RT followed by prophylactic cranial irradiation (PCI) in limited-stage disease, and the use of PCI in extensive-stage disease have improved outcomes, and patient survival has steadily increased in the past decades. This article will review the role of RT in both SCLC and NSCLC, with emphasis at the most recent advances in the field as well as the topics of controversy.
Keywords: Radiation therapy, non-small cell lung cancer, small-cell lung cancer, malignancy, radiosurgery, Inoperable Patients, Stereotactic Radiation Therapy, Chemoradiation, Palliative Radiotherapy, Thoracic Radiation Therapy
Current Respiratory Medicine Reviews
Title: Radiation Therapy in the Management of Lung Cancer
Volume: 7 Issue: 5
Author(s): Tarek Hijal, Jonathan Wan and Luis Souhami
Affiliation:
Keywords: Radiation therapy, non-small cell lung cancer, small-cell lung cancer, malignancy, radiosurgery, Inoperable Patients, Stereotactic Radiation Therapy, Chemoradiation, Palliative Radiotherapy, Thoracic Radiation Therapy
Abstract: Lung cancer is the most commonly diagnosed malignancy and the leading cause of cancer mortality worldwide. Radiation therapy (RT) plays an important role in the management of both small cell (SCLC) and non-small cell lung cancer (NSCLC), as 50 to 60% of patients diagnosed with lung cancer will require RT during the course of their disease. In NSCLC, in addition to the use of RT in advanced stage disease, inoperable patients with early-stage disease are now being treated with highly conformal hypofractionated RT as well as radiosurgery. In SCLC, the use of thoracic chemo-RT followed by prophylactic cranial irradiation (PCI) in limited-stage disease, and the use of PCI in extensive-stage disease have improved outcomes, and patient survival has steadily increased in the past decades. This article will review the role of RT in both SCLC and NSCLC, with emphasis at the most recent advances in the field as well as the topics of controversy.
Export Options
About this article
Cite this article as:
Hijal Tarek, Wan Jonathan and Souhami Luis, Radiation Therapy in the Management of Lung Cancer, Current Respiratory Medicine Reviews 2011; 7 (5) . https://dx.doi.org/10.2174/157339811797189704
DOI https://dx.doi.org/10.2174/157339811797189704 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Emerging Strategies and Challenges for Controlled Delivery of Taxanes: A Comprehensive Review
Current Drug Metabolism The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Current Drug Metabolism Safety Considerations Associated with Development and Clinical Application of Lentiviral Vector Systems for Gene Transfer
Current Genomics Bronchial Thermoplasty: Burn to Cure?
Current Respiratory Medicine Reviews New Target Therapies for Brain Metastases from Breast Cancer
Current Cancer Drug Targets Synthesis and Biological Applications of Triazole Derivatives – A Review
Mini-Reviews in Organic Chemistry A Structure-Function Perspective of Jak2 Mutations and Implications for Alternate Drug Design Strategies: The Road not Taken
Current Medicinal Chemistry Editorial (Hot Topic: Development of New Molecular Agents Targeting Key Signalling Pathways Activated by Growth Factors in Human Cancer)
Current Pharmaceutical Design Volatile Disease Biomarkers in Breath: A Critique
Current Pharmaceutical Biotechnology Advances and Challenges in the Use of Nanoparticles to Optimize PK/PD Interactions of Combined Anti-Cancer Therapies
Current Drug Metabolism Cell Biological Manifestations of Bisdioxopiperazines: Treatment of Human Tumor Cell Lines in Culture
Anti-Cancer Agents in Medicinal Chemistry Pathophysiology of Metastatic Bone Disease and the Role of the Second Generation of Bisphosphonates: From Basic Science to Medicine
Current Pharmaceutical Design Development on PEG-modified Poly (Amino Acid) Copolymeric Micelles for Delivery of Anticancer Drug
Anti-Cancer Agents in Medicinal Chemistry Targeting Tumor Lymphangiogenesis: An Update
Current Medicinal Chemistry MADD Expression in Lung Adenocarcinoma and its Impact on Proliferation and Apoptosis of Lung Adenocarcinoma Cells
Combinatorial Chemistry & High Throughput Screening Tumour Re-Differentiation Effect of Retinoic Acid: A Novel Therapeutic Approach for Advanced Thyroid Cancer
Current Pharmaceutical Design Biochemical Markers of Cardiovascular Damage from Tobacco Smoke
Current Pharmaceutical Design Functionalized Magnetic Nanostructures for Anticancer Therapy
Current Drug Targets Recent Patents for Predictive and Prognostic Biomarkers in Non-Small-Cell Lung Cancer
Recent Patents on Biomarkers Targeting the EGFR Pathway for Cancer Therapy
Current Medicinal Chemistry